Category: BiometSyndicate content

JNJ/Synthes integration continues to bring hefty charges | The week in medtech M&A

October 22, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: JNJ continues to pay hefty integration charges on Synthes deal; Stryker: Mako sales not as strong as we hoped; ConvaTec owners appoint banks to explore sale: sources; BD buys Irish next-gen sequencing startup GenCell Biosystems; Valeant says may raise Allergan bid; beats on profit

JNJ continues to pay hefty integration charges on Synthes deal

October 16, 2014 by Brian Johnson

JNJ continues to pay hefty integration charges on Synthes deal

October 16, 2014 by Brian Johnson

More than 2½ years after it spent $21.3 billion on Synthes, Johnson & Johnson continues to take hefty charges on integrating the orthopedics company into its DePuy franchise.

JNJ continues to pay hefty integration charges on Synthes deal

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biomet's Q1 profits plunge despite sales increases

October 9, 2014 by Brad Perriello

Profits during Biomet's fiscal 1st quarter plunge 77% despite nearly across-the-board sales increases for its orthopedic implants.

Biomet's Q1 profits plunge despite sales increases

Biomet today reported a 77% profit slide for its fiscal 1st quarter, despite posting sales gains across its all but 1 line of orthopedic implants.

Peripherals transition team named in Medtronic, Covidien merger | The week in medtech M&A

October 8, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Medtronic, Covidien name peripherals biz transition team; Medtronic is still in on Covidien buyout; The Street cheers changes to the Medtronic, Covidien deal; Zimmer adds Harvard spinout Etex Corp.; EU to extend Zimmer, Biomet probe

Medtronic, Covidien name peripherals biz transition team

October 1, 2014 by Alex Soule

EU to extend Zimmer, Biomet probe

October 2, 2014 by MassDevice

European anti-trust regulators are extending their probe into the proposed $13 billion merger of orthopedics rivals Zimmer and Biomet.

EU to extend Zimmer, Biomet probe

UPDATED Oct. 2, 2013, with comment from Zimmer.

Zimmer and Biomet update on their mega-merger

September 24, 2014 by Arezu Sarvestani

Zimmer and Biomet provide updates following the 2nd in a series of "Integration Summits" where company leadership is fleshing out the details of their $13 billion merger.

Zimmer and Biomet update on their mega-merger

Leadership at Zimmer (NYSE:ZMH) and Biomet have been on merger overdrive in recent weeks, holding summits and hosting presentations as the companies navigate the tricky business of a $13 billion merger.

Second suitor cedes the field early to Zimmer | Medtech Wall Street news for the week of September 15, 2014

September 18, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Second suitor ceded early to Zimmer in chase for Biomet; Kimberly-Clark readies Halyard Health medical device spinout; InVivo's stock drops as ex-CEO dumps shares; Mevion Medical files for $69M IPO; ReWalk Robotics prices IPO at $36M, below range

Second suitor ceded early to Zimmer in chase for Biomet

September 12, 2014 by Brad Perriello

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp